115 related articles for article (PubMed ID: 25400978)
1. Correlation of CK5 and EGFR with Clinicopathological Profile of Triple-Negative Breast Cancer.
Sood N; Nigam JS
Patholog Res Int; 2014; 2014():141864. PubMed ID: 25400978
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
[TBL] [Abstract][Full Text] [Related]
3. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological Study of Triple Negative Breast Cancers.
Ishitha G; Manipadam MT; Backianathan S; Chacko RT; Abraham DT; Jacob PM
J Clin Diagn Res; 2016 Sep; 10(9):EC05-EC09. PubMed ID: 27790442
[TBL] [Abstract][Full Text] [Related]
6. Triple-Negative Breast Cancer: A Comprehensive Study of Clinical, Histomorphological, and Immunohistochemical Features in Indian Patients.
Sable M; Pai TD; Shet T; Patil A; Dhanavade S; Desai SB
Int J Surg Pathol; 2017 May; 25(3):230-237. PubMed ID: 27612858
[TBL] [Abstract][Full Text] [Related]
7. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
8. Clinico-Pathological Characteristics of Triple Negative and Non Triple Negative High Grade Breast Carcinomas with and Without Basal Marker (CK5/6 and EGFR) Expression at a Rural Tertiary Hospital in India.
Choccalingam C; Rao L; Rao S
Breast Cancer (Auckl); 2012; 6():21-9. PubMed ID: 22346359
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women.
Kanapathy Pillai SK; Tay A; Nair S; Leong CO
BMC Clin Pathol; 2012 Sep; 12():18. PubMed ID: 23009686
[TBL] [Abstract][Full Text] [Related]
10. Double-positive in triple-negative? How significant is basal cytokeratin expression in breast cancer?
Majumder A; Jagani R; Basu A
Med J Armed Forces India; 2020 Jan; 76(1):63-70. PubMed ID: 32020971
[TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas.
Changavi AA; Shashikala A; Ramji AS
J Lab Physicians; 2015; 7(2):79-83. PubMed ID: 26417156
[TBL] [Abstract][Full Text] [Related]
12. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Riaz N; Idress R; Habib S; Lalani EN
Front Oncol; 2020; 10():1083. PubMed ID: 32850312
[No Abstract] [Full Text] [Related]
13. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical profile and morphology in triple - negative breast cancers.
Rao C; Shetty J; Prasad KH
J Clin Diagn Res; 2013 Jul; 7(7):1361-5. PubMed ID: 23998066
[TBL] [Abstract][Full Text] [Related]
15. Triple-Negative Metaplastic Breast Carcinoma: Association of Epidermal Growth Factor Receptor Expression With Prognostic Parameters and Clinical Outcome.
Munawar S; Haider R; Ali SM; Yaqeen SR; Islam S; Asghar IA; Afzal A; Zia S; Irfan M; Hashmi AA
Cureus; 2021 May; 13(5):e15006. PubMed ID: 34150374
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
Zuo T; Wilson P; Cicek AF; Harigopal M
Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
18. Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer.
Wang Z; Liu L; Li Y; Song Z; Jing Y; Fan Z; Zhang S
Front Oncol; 2020; 10():575317. PubMed ID: 33552956
[TBL] [Abstract][Full Text] [Related]
19. [Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].
Liu ZB; Wu J; Ping B; Feng LQ; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):610-4. PubMed ID: 19102940
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
